Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|December 26, 2022
Impact of total marrow/lymphoid irradiation dose to the intestine on graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for hematologic malignanciesSimonetta Saldi, Christian Paolo Luca Fulcheri, Claudio Zucchetti, et al.
Frontiers in Oncology|April 7, 2023
Choline PET/CT in recurrent prostate cancerBeatrice Detti, Maria Grazia Carnevale, Sara Lucidi, et al.
La Radiologia Medica|December 1, 2021
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative settingGiulio Francolini, Giulia Stocchi, Beatrice Detti, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 22, 2023
Modulation of tumor-associated macrophage activity with radiation therapy: a systematic reviewCarlotta Becherini, Andrea Lancia, Beatrice Detti, et al.
Frontiers in Oncology|September 24, 2024
Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?Andrea Lancia, Gianluca Ingrosso, Beatrice Detti, et al.
British Journal of Cancer|April 28, 2017
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric studyLuca Triggiani, Filippo Alongi, Michela Buglione, et al.
Expert Review of Anticancer Therapy|May 21, 2025
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancerGianluca Ingrosso, Andrea Lancia, Lilia Bardoscia, et al.
La Radiologia Medica|November 8, 2021
Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysisMaurizio Valeriani, Beatrice Detti, Andrei Fodor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2023
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)Giulio Francolini, Andrea Gaetano Allegra, Beatrice Detti, et al.
Medical Oncology (Northwood, London, England)|May 19, 2021
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistanceLuca Triggiani, Rosario Mazzola, Davide Tomasini, et al.
Pageof 9